TNF Pharmaceuticals Changes Name to Q/C Technologies, Focuses on Age-Related Diseases and Inflammatory Conditions.
ByAinvest
Wednesday, Sep 24, 2025 9:37 am ET1min read
TNFA--
TNF Pharmaceuticals has changed its name to Q/C Technologies. The company is focused on developing novel therapies for age-related diseases and autoimmune/inflammatory conditions. They are working on two therapeutic platforms: MYMD-1, a drug that regulates the immune system to control chronic inflammation, and Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet